U.S., Feb. 1 -- ClinicalTrials.gov registry received information related to the study (NCT06803589) titled 'Growth Hormone for the Treatment of Gastroparesis' on Jan. 27.
Brief Summary: The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
Study Start Date: Oct. 22, 2024
Study Type: INTERVENTIONAL
Condition:
Gastroparesis
Intervention:
DRUG: Growth Hormone
Subjects will receive growth hormone, Sogroya (Somapacitan-beco injections) via weekly injections for 12 weeks.
For males, the fixed dose will be 0.2 mg/day, 1.5 mg per week
For females, the fixed dose will be 0.3 mg/day, 2.1 mg per week
Recruitment Status: RECRUITING
Sponsor: Mayo Cli...